All News
Filter News
Found 428 articles
-
Arcturus Therapeutics Appoints Lance Kurata as Chief Legal OfficerNationally recognized leader in corporate life sciences transactions
8/6/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the appointment of Lance Kurata as Chief Legal Officer, starting August 10, 2020. Mr. Kurata joins Arcturus from Mintz, where he was a partner in the Corporate Group an
-
Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020
8/4/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2020 after the market close on August 10 and will also provide a corporate overview and financi
-
Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - July 31, 2020
7/31/2020
Arcturus Therapeutics Holdings Inc. announced the closing on July 31, 2020 of its previously announced underwritten public offering of 3,753,773 shares of its common stock at a public offering price of $53.00 per share, which included the exercise in full by the underwriters of their option to purchase up to an additional 489,622 shares of common stock at the public offering price, less underwriting discounts and commissions.
-
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock
7/29/2020
Arcturus Therapeutics Holdings Inc. announced the pricing of an underwritten public offering of 3,264,151 shares of its common stock at a public offering price of $53.00 per share.
-
Arcturus Therapeutics Announces Proposed Public Offering of Common Stock - July 28, 2020
7/28/2020
Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
-
Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19
7/23/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced a binding term sheet with the Israeli Ministry of Health to supply the Company’s COVID-19 vaccine candidate, LUNAR-COV19
-
Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19
7/21/2020
Human dosing of LUNAR-COV19 expected soon Differentiated STARR™ mRNA vaccine expected to produce humoral and cellular immunity at very low doses New preclinical data demonstrates neutralizing antibody titers continue to increase for 50 days after a single administration
-
The two companies will combine their mRNA research to develop the potential vaccines across a range of infectious disease pathogens.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
-
Germany: EIB and European Commission provide CureVac with a €75 million financing for vaccine development and expansion of manufacturing
7/6/2020
European Investment Bank and CureVac sign €75 million loan agreement for the development and large-scale production of vaccines, including CureVac's vaccine candidate against SARS-CoV-2
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 3, 2020.
-
The “printers” are portable, automated messenger RNA (mRNA) production units, which Elon Musk referred to as “RNA microfactories.”
-
Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board
7/1/2020
Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus’ COVID-19 vaccine program, LUNAR-COV19 Company remains on track to begin clinical trial for COVID-19 vaccine this summer SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for ra
-
Arcturus Therapeutics to be Added to Russell 2000® Index
6/29/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it will be added to the Russell 2000 ® Index, as part of the 2020 Russell indexes reconstitution. The addition will be effective after the U.S. market opens on June 29, 2020 as part of th
-
BioSpace Global Roundup, June 18
6/18/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 15, 2020.
-
The collaboration will focus on the development of three of Genmab's bispecific antibodies and will also involve a discovery research collaboration for future antibody therapeutics for cancer.
-
The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate
6/5/2020
- CSL appointed Trusted Manufacturer for University of Queensland's "molecular clamp" enabled COVID-19 vaccine candidate - CEPI and CSL will share costs associated with the clinical development and manufacture of the vaccine candidate - A vaccine is anticipated to be available in 2021 if clinical trials are successful
-
Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency
6/5/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it has dosed the first healthy volunteer in a Phase 1 study with ARCT-810, the Company’s messenger RNA (mRNA)-based therapeutic candidate for Ornithine Transcarbamylase (OTC) deficiency.
-
Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics
5/21/2020
Ultragenyx Pharmaceutical, Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases and Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a leading messenger RNA medicines company, today announced that Ultragenyx has exercised its option to purchase 600,000 shares of Arcturus common stock at $16.00 per share. “We are enco